4.5 Review

Complementary and Alternative Medicine for the Treatment of Gliomas: Scoping Review of Clinical Studies, Patient Outcomes, and Toxicity Profiles

Journal

WORLD NEUROSURGERY
Volume 151, Issue -, Pages E682-E692

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.wneu.2021.04.096

Keywords

Alternative medicine; Complementary medicine; Glioma; Glioblastoma

Ask authors/readers for more resources

A systematic review on CAM use in glioma patients revealed that ketogenic diets, hyperbaric oxygen therapy, and cannabinoids were safe and effective, while carbogen and hypocupremia had no effect on survival but were toxic. Future research is needed to further investigate CAM modalities.
INTRODUCTION: Complementary and alternative medi-cine (CAM) are highly used among those diagnosed with glioma. Further research is warranted, however, as it remains important to clearly delineate CAM practices that are un-proven, disproven, or promising for future research and implementation. METHODS: A systematic review was conducted to identify all articles that investigated the effect of any CAM therapy on survival of patients with newly diagnosed or recurrent glioma. RESULTS: Eighteen papers and 4 abstracts pertaining to the effects of ketogenic diet (4), antioxidants (3), hyperbaric oxygen (4), cannabinoids (2), carbogen and nicotinamide (3), mistletoe extract (2), hypocupremia and penicillamine (1), and overall CAM use (3) on overall and progression-free survival in patients with low-and high-grade glioma were identified (Levels of Evidence I-IV). Ketogenic diets, hyper-baric oxygen therapy, and cannabinoids appear to be safe and well tolerated by patients; preliminary studies demon-strate tumor response and increased progression-free sur-vival and overall survival when combined with standard of care therapies. Antioxidant usage exhibit mixed results perhaps associated with glioma grade with greater effect on low-grade gliomas; vitamin D intake was associated with & nbsp;prolonged survival. Conversely, carbogen breathing and hypocupremia were found to have no effect on the survival of patients with glioma, with associated significant toxicity. Most modalities under the CAM umbrella have not been appropriately studied and require further investigation. CONCLUSIONS: Despite widespread use, Level I or II evidence for CAM for the treatment of glioma is lacking, representing future research directions to optimally counsel and treat glioma patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available